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Acute hepatitis due to brivudin: A case reportq
Alexandre Mottu1, Laura Rubbia-Brandt2, Florian Bihl3,
Antoine Hadengue3, Laurent Spahr3,*
1General Internal Medicine, University Hospitals, Geneva, Switzerland
2Clinical Pathology, University Hospitals, Geneva, Switzerland
3Gastroenterology and Hepatology, University Hospital, 24, Rue Micheli-du-Crest, 1211 Geneva 14, SwitzerlandBackground/Aims:Brivudin is licensed in several European countries for the treatment of herpetic infections, and is
considered safe (1% of patients with transient elevation of liver enzymes) in large multicenter trials.
Methods:We report a case of acute brivudin hepatitis documented with a liver biopsy in detail.
Results:Liver biopsy demonstrated acute liver injury with a predominant cytolytic pattern and features suggestive of a
drug-induced immunoallergic hepatitis. Elevated ALT levels returned to normal within weeks.
Conclusions:This is the ﬁrst published case of acute immunoallergic hepatitis due to brivudin.
 2009 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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Brivudin is a thymidine nucleoside analog with a
potent and selective activity against varicella-zoster
and herpes simplex type 1 viruses [1]. It is licensed in sev-
eral European countries for the treatment of herpes sim-
plex infection (125 mg once daily for 7 days), with
equivalent clinical eﬃcacy as compared to famciclovir
[2], but superior to acyclovir [3], in two large European
multicenter trials. This antiviral agent is considered safe.
In animals given a fairly high dosage of bromovinylde-
oxyuridine (30 mg/kg per day) for a prolonged period
(52 weeks), an increase in ALT and alkaline phospha-
tase was observed [4]. In humans, abnormal liver
enzymes and cGT were reported in 0.8% and 1.1% of0168-8278/$36.00  2009 European Association for the Study of the Liver.
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Abbreviation: ALT, alanine aminotransferase.1019 patients taking the drug for a 7 day period, respec-
tively [2]. Therefore, a 7-day course of brivudin is rec-
ommended for the management of herpes zoster, with
possible extension of treatment duration depending on
disease evolution, with regards to minimal risks and
potential beneﬁts [5]. Thus far, brivudin has not been
associated with symptomatic hepatotoxicity. We report
here in detail an acute liver injury with a predominant
cytolytic pattern in a young patient taking brivudin.2. Case report
A 37-year-old man presented to our hospital on
October 5th, 2008, with fever, asthenia, and vague epi-
gastric pain. There was no history of alcohol consump-
tion or food allergies. He was suﬀering from chronic
episodes of right trigeminal nerve neuralgias due to
recurrent herpes simplex infection, and was under pro-
phylactic valacyclovir to control the symptoms. He
received repeated courses of intravenous immunoglobu-
lin therapy for an isolated IgG3 deﬁciency. Three weeks
before admission, his treatment was changed to brivudin
in association with a low dose of paracetamol (500–Published by Elsevier B.V. All rights reserved.
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that time, liver transaminases and serum bilirubin were
normal. On admission, temperature was 39 C, there
were no cutaneous manifestations, but the liver was
enlarged and tender at physical examination, without
splenomegaly. Laboratory values were as follows: white
blood cells 12 G/L, platelets 143 G/L, C-reactive protein
106 mg/L (N: < 10), procalcitonin 0.16 lg/L (N: < 0.25),
serum bilirubin 14 lmol/L (N: < 25), AST 995 IU/L
(N: < 50), ALT 2348 IU/L (N: < 50), c-glutamyltrans-
peptidase 82 IU/L (N: < 40), alkaline phosphatase 50
IU/L (N: < 125), serum albumin 22 g/L (N: > 35), and
INR was 1.16 with a conserved factor V level. An
abdominal CT scan conﬁrmed the presence of hepato-
megaly, but excluded a biliary tract obstruction and
abdominal collections. As part of an extensive work-
up for infections, the following serological tests were
performed and all tested negative: hepatitis A, B, C, E,
HIV 1 and 2, cytomegalovirus, Epstein–Barr, as well
as Herpes simplex 1 and 2 IgM antibodies. Blood cul-
tures and screening for autoantibodies were also nega-
tive. Brivudin, paracetamol and steroids were stoppedFig. 1. (A) Graphical illustration of ALT (on the left axis) and serum
bilirubin (on the right axis) over time. ULN: upper limit of normal. (B)
Histological view (Haematoxylin-eosin stain, original magniﬁca-
tion  200) demonstrating large zones of parenchymal collapse due to
diﬀuse and conﬂuent hepatocyte necrosis, predominant around the
centrilobular vein (CV). Insert: marked inﬂammatory inﬁltrate of portal
tracts (PT) with prominent eosinophils (original magniﬁcation  400).at admission, and intravenous acyclovir was initiated
in spite of the low probability of ongoing systemic infec-
tion. On day 2 of hospital admission, a liver biopsy was
performed, showing conﬂuent centrilobular necrosis
with reticulin collapse, as well as inﬂamed portal tracts
with numerous polynuclear eosinophils. Acyclovir was
stopped, and the patient gradually improved clinically
and biologically over the following days and was dis-
charged from hospital on October 13th. Transient blood
eosinophilia (1300/mm3) was observed at day 4 of hos-
pitalization. Serum bilirubin and transaminases were
normal on November 7th, 33 days after the onset of
acute hepatitis. Fig. 1 illustrates both the time course
of biological alterations and the histological ﬁndings at
liver biopsy.3. Discussion
That brivudin appears responsible for the observed
liver injury seems quite compelling based on the tempo-
ral relationship between administration of the drug and
the onset of clinical symptoms, the fact that other med-
ications were discontinued, the marked ALT level eleva-
tion together with the liver biopsy ﬁndings, the absence
of alternative diagnosis, and the dechallenge with dis-
continuation of the drug. To assess the likelihood of a
causal association between brivudin exposure and the
acute hepatitis, we utilized drug-induced liver injury
diagnostic scales. Thus, the strength of association
between the implicated antiviral and the acute hepato-
cellular damage was graded as ‘‘highly probable” using
the Roussel Uclaf Causality Assessment Method
(RUCAM) scale [6] (score of 9), and ‘‘probable” using
both the Danan and Benichou [7] (score of 8) and the
Maria and Victorino [8] (score of 14) scales. In the latter
scales, the elements missing for a closer association
included the absence of a previous report of hepatotox-
icity due to brivudin, the absence of cutaneous manifes-
tations, no risk factors, and no re-exposure to the drug.
Liver biopsy is not routinely recommended when
drug-induced liver injury is suspected. When it is per-
formed, it may provide important information on the
pattern of liver injury (cytolytic, cholestastic, or mixed)
and demonstrate histological features suggestive of
drug-induced liver injury [9]. In this young patient, the
pattern was predominantly cytolytic, as reported [10],
and the marked portal tract eosinophilic inﬁltration
was highly suggestive of an immunoallergic mechanism.References
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